CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate
CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate
AstraZeneca (NASDAQ:AZN) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from
阿斯利康（纳斯达克：AZN）报告了每股调整后的季度盈利为0.99美元，低于分析师共识预期的1.20美元，下降了17.5％。这比去年同期每股盈利1.07美元下降了7.91％。
AstraZeneca (NASDAQ:AZN) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $12.98 billion which beat the analyst consensus estimate of $12.75 billion by 1.83 percent. This is a 13.73 percent increase over sales of $11.42 billion the same period last year.
阿斯利康（纳斯达克：AZN）报告了每股调整后的季度盈利为0.99美元，低于分析师共识预期的1.20美元，下降了17.5％。这比去年同期每股盈利1.07美元下降了7.91％。该公司报告的季度销售额为129.8亿美元，超过分析师共识预期的127.5亿美元，增长了1.83％。这比去年同期的销售额114.2亿美元增长了13.73％。